TrialThe journal of headache and pain2017

A multicenter, open-label, long-term safety and tolerability study of DFN-02, an intranasal spray of sumatriptan 10 mg plus permeation enhancer DDM, for the acute treatment of episodic migraine.

Sagar Munjal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.